Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

UK-based healthtech startup Medopad raises €22.5M in Series B investment led by Leaps by Bayers

Editorial team by Editorial team
November 5, 2019
in Startups, (Crowd)funding, Health & Medtech, News, Software & SaaS
0
UK-based healthtech startup Medopad raises €22.5M in Series B investment led by Leaps by Bayers
52
SHARES
LinkedInTwitterWhatsAppFacebook

New age health startups are all the rage right now and rightly so since they are introducing new ways to better our health and lives. By leveraging some of the cutting edge technologies available, many medtech startups have already made a name for themselves. The UK-based healthtech startup Medopad is one such company that has come a long way since it was established in 2011.

Funding details

Medopad has announced of securing €22.5M in Series B round of investment, which was led by Leaps By Bayers. With the new investment, Medopad’s total amount raised till now stands over €45 million and with the freshly acquired funds, the company aims to support new clinical studies, including digital biomarker discovery and creation of digital therapeutics (DTx). It will also focus on technology development, geographic expansion and

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Commercial growth through strategic collaborations

The founder and CEO of Medopad, Dan Vahdat, says, “Medopad has a bold mission to help people live their life to the fullest – one that requires long-term commitment and partnership to achieve. We are delighted that Leaps by Bayer who participated in our Series A round have now become the lead investor in our Series B. We have found the ideal partner with the dedication to help us reach our vision of creating a world where each person lives their life to the fullest.”

Funding new research for Digital Biomarkers

Medopad was founded in 2011 by Dan Vahdat and Rich Khatib. The company teams up with scientists, healthcare and pharmaceutical professionals, and technologists to build proactive healthcare category via a portfolio of DTx and digital biomarkers. These digital biomarkers are a relatively new category in healthcare that collates data to risk predict, detect condition progression and enable diagnosis through digital technologies. The new Series B investments will be used by the company to discover digital biomarkers and develop DTx.

Medopad currently has several clinical trials underway to develop new digital biomarkers for conditions like Aortic Stenosis (AS), Parkinson’s, Diabetic Neuropathy, and Depression. With its modular approach that covers a wide variety of disease areas to deliver better and more personalised care, the startup aims to transform the way patients and data interact with clinicians.

Image credits: Medopad

Stay tuned to Silicon Canals for more European technology news.

SCA: A litmus test for Europe!

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: fundingstartup
Share3Tweet11SendShare27

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Here’s how cryptocurrency will take over the world

Blue Tulip Awards is driven by purpose: why innovation and equality go hand in hand

Future of coding: CTOs discuss low-code versus custom code software development for their business

Breaking news from Amsterdam | Partner

Here’s why Just Eat Takeaway is expanding its offices in Amsterdam

Amsterdam-based Veylinx uses Nobel Prize-winning approach to solve the problem of unreliable survey data; raises €1.6M

Amsterdam-based fintech unicorn Mollie enters UK market to helps merchants there grow into Europe post-Brexit

Amsterdam-based HR tech Recruitee takes a “shortcut” to a future unicorn status

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info